Hepatic fat reduction: Resmetirom showed a significant relative decrease in hepatic fat vs. placebo at week 12 (−32.9% vs. −10.4%, p<0.0001) and week 36 (−37.3% vs. −8.9%, p<0.0001).  MASH resolution: 27% of Resmetirom-treated patients vs. 6% placebo (p=0.018).  Lipid reduction: Significant decreases in LDL-C (−16.2%), triglycerides (−21.4%), and lipoprotein (a) (−22.7%). Liver enzymes: Reduced ALT (−15.4 U/L, p=0.0019) and AST.  Fibrosis biomarkers: Improved PRO-C3 and enhanced liver fibrosis scores. Here, GPT is linked to Hepatic fibrosis.